ImmunityBio Files 8-K: Material Agreement, Other Events
Ticker: IBRX · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $459,972,480 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-filing, regulatory-update
Related Tickers: IBIO
TL;DR
IBIO filed an 8-K on 12/23/25 for a material agreement and other events.
AI Summary
On December 23, 2025, ImmunityBio, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in San Diego, California.
Why It Matters
This 8-K filing indicates significant corporate activity, including a material definitive agreement, which could impact the company's strategic direction and financial performance.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to significant stock price movements, warranting a medium risk assessment.
Key Numbers
- 001-37507 — SEC File Number (Identifies the company's filing with the SEC.)
- 43-1979754 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- December 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Address of principal executive offices
- NantKwest, Inc. (company) — Former company name
- Conkwest, Inc. (company) — Former company name
- ZelleRx Corp (company) — Former company name
FAQ
What is the nature of the material definitive agreement filed on December 23, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What other events are reported in this 8-K filing?
The filing mentions 'Other Events' as an item information, but the specifics of these events are not detailed in the provided text.
When was ImmunityBio, Inc. previously known as NantKwest, Inc.?
The date of the name change from NantKwest, Inc. to ImmunityBio, Inc. was July 13, 2015.
What is ImmunityBio, Inc.'s SIC code?
The Standard Industrial Classification (SIC) code for ImmunityBio, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Where are ImmunityBio, Inc.'s principal executive offices located?
ImmunityBio, Inc.'s principal executive offices are located at 3530 John Hopkins Court, San Diego, California, 92121.
Filing Stats: 1,030 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2025-12-23 19:25:40
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Se
- $459,972,480 — uthorizes the issuance of an additional $459,972,480 of Shares, which were registered under
Filing Documents
- d61833d8k.htm (8-K) — 32KB
- d61833dex31.htm (EX-3.1) — 6KB
- d61833dex51.htm (EX-5.1) — 9KB
- d61833dex101.htm (EX-10.1) — 14KB
- g61833g1223191314206.jpg (GRAPHIC) — 3KB
- 0001193125-25-331244.txt ( ) — 184KB
- ibrx-20251223.xsd (EX-101.SCH) — 3KB
- ibrx-20251223_lab.xml (EX-101.LAB) — 17KB
- ibrx-20251223_pre.xml (EX-101.PRE) — 11KB
- d61833d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 3.1* Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio, Inc. dated November 10, 2025. 5.1* Legal Opinion of Wilson Sonsini Goodrich & Rosati, P.C. 10.1* Amendment No. 1 to Open Market Sale Agreement dated December 23, 2025, by and between ImmunityBio, Inc. and Jefferies LLC. 23.1* Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: December 23, 2025 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer